ABPI releases report on fair patient access to clinical trials and treatments

Article summary

The Association of the British Pharmaceutical Industry (ABPI) has released a new report titled ‘How to make sure patients get faster, more equitable access to innovative treatments’, which explores the human cost of NHS decisions and processes that fail to ensure fair and timely patient access to clinical trials and proven treatments. The report focuses on three key stages- patient access challenges during the clinical stages of a medicine’s development, when the NHS adopts medicines after approval is given by regulators and at the point of patient access to treatment. This report builds on a previous ABPI and PwC report published in May 2022 that focused on 13 medicines in line with NICE recommendations across stroke prevention, kidney disease, asthma and type 2 diabetes and found that 1.2 million patients are missing out on innovative treatments.